Vaxart, Inc. (VXRT)
| Market Cap | 136.46M |
| Revenue (ttm) | 16.76M |
| Net Income (ttm) | -72.34M |
| Shares Out | 227.44M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,612,182 |
| Open | 0.608 |
| Previous Close | 0.599 |
| Day's Range | 0.590 - 0.620 |
| 52-Week Range | 0.520 - 1.540 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+400.0%) |
| Earnings Date | Nov 13, 2024 |
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic... [Read more]
Financial Performance
In 2023, Vaxart's revenue was $7.38 million, an increase of 6796.26% compared to the previous year's $107,000. Losses were -$82.47 million, -23.47% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 400.00% from the latest price.
News
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Offic...
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinica...
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine compa...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board ...
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Off...
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
Vaxart Inc is developing oral vaccines for COVID-19, norovirus, and influenza with promising early clinical results but financial struggles. Vaxart received $453M funding from BARDA for a 10,000-patie...
Vaxart Provides Business Update
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and re...
Vaxart Announces $40 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering p...
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean T...
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (G...
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccin...
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended Decem...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif.
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity again...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the...
Vaxart, Inc. Announces Management Change
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D.
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosin...